Matchett, K. P.
Wilson-Kanamori, J. R. http://orcid.org/0000-0002-1372-9912
Portman, J. R.
Kapourani, C. A. http://orcid.org/0000-0003-2303-1953
Fercoq, F. http://orcid.org/0000-0002-4825-024X
May, S. http://orcid.org/0000-0003-0095-7403
Zajdel, E.
Beltran, M. http://orcid.org/0000-0001-8321-2479
Sutherland, E. F.
Mackey, J. B. G.
Brice, M. http://orcid.org/0000-0002-0135-915X
Wilson, G. C.
Wallace, S. J. http://orcid.org/0000-0002-1826-0551
Kitto, L.
Younger, N. T.
Dobie, R.
Mole, D. J. http://orcid.org/0000-0001-6884-7302
Oniscu, G. C. http://orcid.org/0000-0003-1714-920X
Wigmore, S. J. http://orcid.org/0000-0002-3614-8002
Ramachandran, P. http://orcid.org/0000-0001-5996-2413
Vallejos, C. A. http://orcid.org/0000-0003-3638-1960
Carragher, N. O.
Saeidinejad, M. M. http://orcid.org/0000-0002-1724-4496
Quaglia, A.
Jalan, R. http://orcid.org/0000-0002-7747-4015
Simpson, K. J.
Kendall, T. J. http://orcid.org/0000-0002-4174-2786
Rule, J. A.
Lee, W. M.
Hoare, M. http://orcid.org/0000-0001-5990-9604
Weston, C. J. http://orcid.org/0000-0002-9651-1264
Marioni, J. C.
Teichmann, S. A. http://orcid.org/0000-0002-6294-6366
Bird, T. G. http://orcid.org/0000-0002-6120-1581
Carlin, L. M. http://orcid.org/0000-0001-7172-5234
Henderson, N. C. http://orcid.org/0000-0002-2273-4094
Article History
Received: 8 February 2023
Accepted: 2 April 2024
First Online: 1 May 2024
Competing interests
: N.C.H. has received research funding from AbbVie, Pfizer, Gilead, Boehringer-Ingelheim and Galecto, and is an advisor or consultant for AstraZeneca, GSK, MSD, Galecto and Pliant Therapeutics. R.J. is an inventor of OPA (licensed to Mallinckrodt Pharma) and founder of Yaqrit Discovery, Hepyx Limited and Cyberliver. All other authors declare no competing interests.